Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond
Emir Muzurović, Niki Katsiki, Špela Volčanšek, Fulvio Plescia, Manfredi Rizzo, Christos S. Mantzoros
Topics & Concepts
MedicineLixisenatideIncretinClinical trialExenatideIntensive care medicineDiabetes mellitusDrug developmentDiseaseObesityBioinformaticsType 2 diabetesNeurocognitiveGlucagon-like peptide-1Kidney diseasePharmacologyCoronary artery diseaseDrugType 2 Diabetes MellitusTherapeutic approachAmylinWeight lossSaxagliptinRisk factorClinical PracticePharmacotherapyDosingAtherosclerotic cardiovascular diseaseInternal medicinePosition paperPrecision medicinePeptide YYManagement of obesityDiabetes Treatment and ManagementBariatric Surgery and OutcomesRegulation of Appetite and Obesity